Chlorhexidine as a Keap1-Nrf2 inhibitor: a new target for an old drug for Parkinson's disease therapy

References

• Afennich, F., Slot, D., Hossainian, N., & Van der Weijden, G. (2011). The effect of hexetidine mouthwash on the prevention of plaque and gingival inflammation: A systematic review. International Journal of Dental Hygiene, 9(3), 182–190.
   PubMed Web of Science ®Google Scholar
• Bengoa-Vergniory, N., Fields, C., & Wade-Martins, R. (2019) Targeting alpha-synuclein as a therapy for Parkinsonâ€TMs disease. Frontiers in Molecular Neuroscience, 12, 299. https://doi.org/10.3389/fnmol.2019.00299
   Google Scholar
• Bowers, K. J., Chow, D. E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., Klepeis, J. L., Kolossvary, I., Moraes, M. A., & Sacerdoti, F. D. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, 43–43.
   Google Scholar
• Chambers, J. M. (2008). Software for data analysis: Programming with R (Vol. 2). Springer.
   Google Scholar
• Davies, T. G., Wixted, W. E., Coyle, J. E., Griffiths-Jones, C., Hearn, K., McMenamin, R., Norton, D., Rich, S. J., Richardson, C., Saxty, G., Willems, H. M. G., Woolford, A. J.-A., Cottom, J. E., Kou, J.-P., Yonchuk, J. G., Feldser, H. G., Sanchez, Y., Foley, J. P., Bolognese, B. J., … Kerns, J. K. (2016). Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: Nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) Protein-protein interaction with high cell potency identified by fragment-based discovery. Journal of Medicinal Chemistry, 59(8), 3991–4006. https://doi.org/10.1021/acs.jmedchem.6b00228
   PubMed Web of Science ®Google Scholar
• DeLano, W. L. (2002). Pymol: An open-source molecular graphics tool. CCP4 Newsletter on Protein Crystallography, 40(1), 82–92.
   Google Scholar
• Deshmukh, P., Unni, S., Krishnappa, G., & Padmanabhan, B. (2017). The Keap1-Nrf2 pathway: Promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophysical Reviews, 9(1), 41–56. https://doi.org/10.1007/s12551-016-0244-4
   PubMedGoogle Scholar
• Fahn, S., & Sulzer, D. (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, 1(1), 139–154. https://doi.org/10.1602/neurorx.1.1.139
   PubMedGoogle Scholar
• Freimoser, F. M., Jakob, C. A., Aebi, M., & Tuor, U. (1999). The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities. Applied and Environmental Microbiology, 65(8), 3727–3729. https://doi.org/10.1128/AEM.65.8.3727-3729.1999
   PubMed Web of Science ®Google Scholar
• Gelano, T. F., Bacha, Y. D., & Abate, D. (2019). Effect of chlorhexidine cord application on prevention of neonatal sepsis in developing countries: Systematic review and meta-analysis. International Journal of Health Sciences, 13(1), 40–51.
   Google Scholar
• Gunsolley, J. C. (2010). Clinical efficacy of antimicrobial mouthrinses. Journal of Dentistry, 38, S6–S10. https://doi.org/10.1016/S0300-5712(10)70004-X
   PubMed Web of Science ®Google Scholar
• Heightman, T. D., Callahan, J. F., Chiarparin, E., Coyle, J. E., Griffiths-Jones, C., Lakdawala, A. S., McMenamin, R., Mortenson, P. N., Norton, D., Peakman, T. M., Rich, S. J., Richardson, C., Rumsey, W. L., Sanchez, Y., Saxty, G., Willems, H. M. G., Wolfe, L., Woolford, A. J.-A., Wu, Z., … Davies, T. G. (2019). Structure-activity and structure-conformation relationships of aryl propionic acid inhibitors of the kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 (KEAP1/NRF2) protein-protein interaction. Journal of Medicinal Chemistry, 62(9), 4683–4702. https://doi.org/10.1021/acs.jmedchem.9b00279
   PubMed Web of Science ®Google Scholar
• Jain, A. D., Potteti, H., Richardson, B. G., Kingsley, L., Luciano, J. P., Ryuzoji, A. F., Lee, H., Krunic, A., Mesecar, A. D., Reddy, S. P., & Moore, T. W. (2015). Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. European Journal of Medicinal Chemistry, 103, 252–268.
   PubMed Web of Science ®Google Scholar
• James, P., Worthington, H. V., Parnell, C., Harding, M., Lamont, T., Cheung, A., Whelton, H., & Riley, P. (2017). Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database of Systematic Reviews, 3. https://doi.org/10.1002/14651858.CD008676.pub2
   Google Scholar
• Jnoff, E., Albrecht, C., Barker, J. J., Barker, O., Beaumont, E., Bromidge, S., Brookfield, F., Brooks, M., Bubert, C., Ceska, T., Corden, V., Dawson, G., Duclos, S., Fryatt, T., Genicot, C., Jigorel, E., Kwong, J., Maghames, R., Mushi, I., … Courade, J.-P. (2014). Binding mode and structure–activity relationships around direct inhibitors of the Nrf2–Keap1 complex. ChemMedChem, 9(4), 699–705.
   PubMed Web of Science ®Google Scholar
• Kang, J.-Q., Chong, Z. Z., & Maiese, K. (2003). Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. Journal of Neuroscience Research, 74(1), 37–51.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today. Technologies, 1(4), 337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
   PubMedGoogle Scholar
• Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017). Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxidative Medicine and Cellular Longevity, 2017, 2525967. https://doi.org/10.1155/2017/2525967
   PubMed Web of Science ®Google Scholar
• Löe, H., & Schiott, C. R. (1970). The effect of mouthrinses and topical application of chlorhexidine on the development of dental plaque and gingivitis in man. Journal of Periodontal Research, 5(2), 79–83.
   PubMedGoogle Scholar
• Marcotte, D., Zeng, W., Hus, J.-C., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A., Enyedy, I., Cuervo, H., Wang, D., Atmanene, C., Roecklin, D., Vecchi, M., Vivat, V., Kraemer, J., Winkler, D., Hong, V., Chao, J., Lukashev, M., & Silvian, L. (2013). Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorganic & Medicinal Chemistry, 21(14), 4011–4019. https://doi.org/10.1016/j.bmc.2013.04.019
   PubMed Web of Science ®Google Scholar
• Oprea, T. I., & Mestres, J. (2012). Drug repurposing: Far beyond new targets for old drugs. The AAPS Journal, 14(4), 759–763.
   PubMed Web of Science ®Google Scholar
• Padmanabhan, B., Tong, K. I., Kobayashi, A., Yamamoto, M., & Yokoyama, S. (2008). Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1. Journal of Synchrotron Radiation, 15(Pt 3), 273–276.
   PubMedGoogle Scholar
• Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006). Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular Cell, 21(5), 689–700.
   PubMed Web of Science ®Google Scholar
• Protein Preparation Wizard. (2017). 4: Schrödinger suite 2017-4 protein preparation wizard. New York: Schrödinger, LLC.
   Google Scholar
• Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58.
   PubMed Web of Science ®Google Scholar
• Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Oxidative stress, inflammation, and cancer: How are they linked? Free Radical Biology & Medicine, 49(11), 1603–1616.
   PubMed Web of Science ®Google Scholar
• Schweiger, R., Soll, J., Jung, K., Heermann, R., & Schwenkert, S. (2013). Quantification of interaction strengths between chaperones and tetratricopeptide repeat domain-containing membrane proteins. The Journal of Biological Chemistry, 288(42), 30614–30625.
   PubMed Web of Science ®Google Scholar
• Seidel, S. A. I., Dijkman, P. M., Lea, W. A., van den Bogaart, G., Jerabek-Willemsen, M., Lazic, A., Joseph, J. S., Srinivasan, P., Baaske, P., Simeonov, A., Katritch, I., Melo, F. A., Ladbury, J. E., Schreiber, G., Watts, A., Braun, D., & Duhr, S. (2013). Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods (San Diego, CA), 59(3), 301–315.
   PubMed Web of Science ®Google Scholar
• Sulzer, D., & Surmeier, D. J. (2013). Neuronal vulnerability, pathogenesis, and Parkinson's disease. Movement Disorders, 28(6), 715–724.
   PubMed Web of Science ®Google Scholar
• Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007). Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Molecular and Cellular Biology, 27(21), 7511–7521.
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
   PubMed Web of Science ®Google Scholar
• Unni, S., Deshmukh, P., Krishnappa, G., Kommu, P., & Padmanabhan, B. (2021). Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1. The FEBS Journal, 288(5), 1599–1613. https://doi.org/10.1111/febs.15485
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk, J. M., Vega, I. E., & Brundin, P. (2017). Oxidative stress in neurodegenerative disease: Causation or association? Oncotarget, 8(7), 10777–10778. https://doi.org/10.18632/oncotarget.14650
   PubMedGoogle Scholar
• Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., … Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082. https://doi.org/10.1093/nar/gkx1037
   PubMed Web of Science ®Google Scholar
• Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., & Woolsey, J. (2006). DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research, 34(Database issue), D668–D672.
   PubMed Web of Science ®Google Scholar
• Wolber, G., Dornhofer, A. A., & Langer, T. (2006). Efficient overlay of small organic molecules using 3D pharmacophores. Journal of Computer-Aided Molecular Design, 20(12), 773–788.
   PubMed Web of Science ®Google Scholar
• Wolber, G., & Langer, T. (2005). LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of Chemical Information and Modeling, 45(1), 160–169.
   PubMed Web of Science ®Google Scholar
• Zhong, M., Lynch, A., Muellers, S. N., Jehle, S., Luo, L., Hall, D. R., Iwase, R., Carolan, J. P., Egbert, M., Wakefield, A., Streu, K., Harvey, C. M., Ortet, P. C., Kozakov, D., Vajda, S., Allen, K. N., & Whitty, A. (2020). Interaction energetics and druggability of the protein–protein interaction between Kelch-like ECH-associated protein 1 (KEAP1) and Nuclear factor erythroid 2 Like 2 (Nrf2). Biochemistry, 59(4), 563–581. https://doi.org/10.1021/acs.biochem.9b00943
   PubMed Web of Science ®Google Scholar